Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 61 entries
Sorted by: Best Match Show Resources per page
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 12616965
Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(10):703-29
Bayés, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(10), 703-29.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,10 (2002): 703-29.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29. PMID: 12616965.
Copy Download .nbib Format: NLM
Class III Antiarrhythmic Effects of Dofetilide in Rabbit Atrial Myocardium.

Journal of cardiovascular pharmacology and therapeutics

Pallandi RT, Lovell NH, Campbell TJ.
PMID: 10684421
J Cardiovasc Pharmacol Ther. 1996 Jul;1(3):229-234. doi: 10.1053/jcpt.1996.0229.

BACKGROUND: Dofetilide is a new class III antiarrhythmic agent with demonstrated efficacy in ventricular and atrial tachyarrhythmias. We investigated its class III actions and their modulation by stimulation rate in rabbit atrial myocardium. METHODS AND RESULTS: Standard microelectrode techniques...

Cite
Pallandi RT, Lovell NH, Campbell TJ. Class III Antiarrhythmic Effects of Dofetilide in Rabbit Atrial Myocardium. J Cardiovasc Pharmacol Ther. 1996;1(3):229-234doi: 10.1053/jcpt.1996.0229.
Pallandi, R. T., Lovell, N. H., & Campbell, T. J. (1996). Class III Antiarrhythmic Effects of Dofetilide in Rabbit Atrial Myocardium. Journal of cardiovascular pharmacology and therapeutics, 1(3), 229-234. https://doi.org/10.1053/jcpt.1996.0229
Pallandi, et al. "Class III Antiarrhythmic Effects of Dofetilide in Rabbit Atrial Myocardium." Journal of cardiovascular pharmacology and therapeutics vol. 1,3 (1996): 229-234. doi: https://doi.org/10.1053/jcpt.1996.0229
Pallandi RT, Lovell NH, Campbell TJ. Class III Antiarrhythmic Effects of Dofetilide in Rabbit Atrial Myocardium. J Cardiovasc Pharmacol Ther. 1996 Jul;1(3):229-234. doi: 10.1053/jcpt.1996.0229. PMID: 10684421.
Copy Download .nbib Format: NLM
Concomitant Block of the Rapid (I(Kr)) and Slow (I(Ks)) Components of the Delayed Rectifier Potassium Current is Associated With Additional Drug Effects on Lengthening of Cardiac Repolarization.

Journal of cardiovascular pharmacology and therapeutics

Geelen P, Drolet B, Lessard E, Gilbert P, O'Hara GE, Turgeon J.
PMID: 10684535
J Cardiovasc Pharmacol Ther. 1999 Jul;4(3):143-150. doi: 10.1177/107424849900400303.

BACKGROUND: The delayed rectifier potassium current, which comprises both a rapid (I(Kr)) and as slow (I(Ks)) component, is a major outward current involved in repolarization of cardiac myocytes. I(Kr) is the target of most drugs that prolong repolarization, whereas...

Cite
Geelen P, Drolet B, Lessard E, et al. Concomitant Block of the Rapid (I(Kr)) and Slow (I(Ks)) Components of the Delayed Rectifier Potassium Current is Associated With Additional Drug Effects on Lengthening of Cardiac Repolarization. J Cardiovasc Pharmacol Ther. 1999;4(3):143-150doi: 10.1177/107424849900400303.
Geelen, P., Drolet, B., Lessard, E., Gilbert, P., O'Hara, G. E., & Turgeon, J. (1999). Concomitant Block of the Rapid (I(Kr)) and Slow (I(Ks)) Components of the Delayed Rectifier Potassium Current is Associated With Additional Drug Effects on Lengthening of Cardiac Repolarization. Journal of cardiovascular pharmacology and therapeutics, 4(3), 143-150. https://doi.org/10.1177/107424849900400303
Geelen, et al. "Concomitant Block of the Rapid (I(Kr)) and Slow (I(Ks)) Components of the Delayed Rectifier Potassium Current is Associated With Additional Drug Effects on Lengthening of Cardiac Repolarization." Journal of cardiovascular pharmacology and therapeutics vol. 4,3 (1999): 143-150. doi: https://doi.org/10.1177/107424849900400303
Geelen P, Drolet B, Lessard E, Gilbert P, O'Hara GE, Turgeon J. Concomitant Block of the Rapid (I(Kr)) and Slow (I(Ks)) Components of the Delayed Rectifier Potassium Current is Associated With Additional Drug Effects on Lengthening of Cardiac Repolarization. J Cardiovasc Pharmacol Ther. 1999 Jul;4(3):143-150. doi: 10.1177/107424849900400303. PMID: 10684535.
Copy Download .nbib Format: NLM
Current and emerging antiarrhythmic drug therapy for ventricular tachycardia.

Cardiology and therapy

Williams ES, Viswanathan MN.
PMID: 25135287
Cardiol Ther. 2013 Jun;2(1):27-46. doi: 10.1007/s40119-013-0012-5. Epub 2013 Feb 20.

Ventricular arrhythmias, including ventricular fibrillation (VF) and sustained ventricular tachycardia (VT), are the principal causes of sudden cardiac death in patients with structural heart disease. While coronary artery disease is the predominant substrate associated with the development of VT,...

Cite
Williams ES, Viswanathan MN. Current and emerging antiarrhythmic drug therapy for ventricular tachycardia. Cardiol Ther. 2013;2(1):27-46doi: 10.1007/s40119-013-0012-5.
Williams, E. S., & Viswanathan, M. N. (2013). Current and emerging antiarrhythmic drug therapy for ventricular tachycardia. Cardiology and therapy, 2(1), 27-46. https://doi.org/10.1007/s40119-013-0012-5
Williams, Eric S, and Viswanathan, Mohan N. "Current and emerging antiarrhythmic drug therapy for ventricular tachycardia." Cardiology and therapy vol. 2,1 (2013): 27-46. doi: https://doi.org/10.1007/s40119-013-0012-5
Williams ES, Viswanathan MN. Current and emerging antiarrhythmic drug therapy for ventricular tachycardia. Cardiol Ther. 2013 Jun;2(1):27-46. doi: 10.1007/s40119-013-0012-5. Epub 2013 Feb 20. PMID: 25135287; PMCID: PMC4107437.
Copy Download .nbib Format: NLM
[Congestive heart failure and sudden cardiac death: Pharmacological and non pharmacological treatment strategies].

Zeitschrift fur Kardiologie

Schmitt C.
PMID: 27320526
Z Kardiol. 2000 Oct;89:55-9. doi: 10.1007/PL00022886.

Recent multicenter studies have shown that the implantable cardioverter defibrillator (ICD) is superior compared to antiarrhythmic agents after sudden cardiac death (SCD) in patients with congestive heart failure. Further ICD studies have to be performed for primary prevention of...

Cite
Schmitt C. Herzinsuffizienz und plötzlicher Herztod - Medikamentöse und nicht medikamentöse therapeutische Möglichkeiten aus der Sicht des Rhythmologen. [Congestive heart failure and sudden cardiac death: Pharmacological and non pharmacological treatment strategies]. Z Kardiol. 2000;89:55-9doi: 10.1007/PL00022886.
Schmitt, C. (2000). Herzinsuffizienz und plötzlicher Herztod - Medikamentöse und nicht medikamentöse therapeutische Möglichkeiten aus der Sicht des Rhythmologen. [Congestive heart failure and sudden cardiac death: Pharmacological and non pharmacological treatment strategies]. Zeitschrift fur Kardiologie, 8955-9. https://doi.org/10.1007/PL00022886
Schmitt, C. "Herzinsuffizienz und plötzlicher Herztod - Medikamentöse und nicht medikamentöse therapeutische Möglichkeiten aus der Sicht des Rhythmologen." [Congestive heart failure and sudden cardiac death: Pharmacological and non pharmacological treatment strategies]. Zeitschrift fur Kardiologie vol. 89 (2000): 55-9. doi: https://doi.org/10.1007/PL00022886
Schmitt C. Herzinsuffizienz und plötzlicher Herztod - Medikamentöse und nicht medikamentöse therapeutische Möglichkeiten aus der Sicht des Rhythmologen. [Congestive heart failure and sudden cardiac death: Pharmacological and non pharmacological treatment strategies]. Z Kardiol. 2000 Oct;89:55-9. doi: 10.1007/PL00022886. German. PMID: 27320526.
Copy Download .nbib Format: NLM
Safety of Inpatient Dofetilide Initiation per Cardiology Services: A Retrospective Review.

Journal of pharmacy practice

Cicirale C, Jackson J, Gothard D.
PMID: 33736527
J Pharm Pract. 2021 Mar 19;8971900211000212. doi: 10.1177/08971900211000212. Epub 2021 Mar 19.

INTRODUCTION: Dofetilide is an antiarrhythmic medication that has the potential to cause life threatening arrhythmias, such as Torsade de pointes. The 2014 ACC/AHA/HRS guidelines for the management of patients with atrial fibrillation state that patients need to meet certain...

Cite
Cicirale C, Jackson J, Gothard D. Safety of Inpatient Dofetilide Initiation per Cardiology Services: A Retrospective Review. J Pharm Pract. 2021;8971900211000212doi: 10.1177/08971900211000212.
Cicirale, C., Jackson, J., & Gothard, D. (2021). Safety of Inpatient Dofetilide Initiation per Cardiology Services: A Retrospective Review. Journal of pharmacy practice, 8971900211000212. https://doi.org/10.1177/08971900211000212
Cicirale, Carrie, et al. "Safety of Inpatient Dofetilide Initiation per Cardiology Services: A Retrospective Review." Journal of pharmacy practice vol. (2021): 8971900211000212. doi: https://doi.org/10.1177/08971900211000212
Cicirale C, Jackson J, Gothard D. Safety of Inpatient Dofetilide Initiation per Cardiology Services: A Retrospective Review. J Pharm Pract. 2021 Mar 19;8971900211000212. doi: 10.1177/08971900211000212. Epub 2021 Mar 19. PMID: 33736527.
Copy Download .nbib Format: NLM
Refractory Torsades de Pointes Due to Dofetilide Overdose.

Journal of investigative medicine high impact case reports

Crosby J, Bhopalwala H, Kharawala A, Dewaswala N, Ganti SS, Bhopalwala A.
PMID: 34894807
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211056492. doi: 10.1177/23247096211056492.

Dofetilide, a class III antiarrhythmic, is widely used in the treatment of cardiac arrhythmias. Antiarrhythmic drugs can have a long duration of action that prolongs the QT interval. This causes bradycardia that predisposes to R-on-T phenomenon subsequently leading to...

Cite
Crosby J, Bhopalwala H, Kharawala A, et al. Refractory Torsades de Pointes Due to Dofetilide Overdose. J Investig Med High Impact Case Rep. 2021;9:23247096211056492doi: 10.1177/23247096211056492.
Crosby, J., Bhopalwala, H., Kharawala, A., Dewaswala, N., Ganti, S. S., & Bhopalwala, A. (2021). Refractory Torsades de Pointes Due to Dofetilide Overdose. Journal of investigative medicine high impact case reports, 923247096211056492. https://doi.org/10.1177/23247096211056492
Crosby, James, et al. "Refractory Torsades de Pointes Due to Dofetilide Overdose." Journal of investigative medicine high impact case reports vol. 9 (2021): 23247096211056492. doi: https://doi.org/10.1177/23247096211056492
Crosby J, Bhopalwala H, Kharawala A, Dewaswala N, Ganti SS, Bhopalwala A. Refractory Torsades de Pointes Due to Dofetilide Overdose. J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211056492. doi: 10.1177/23247096211056492. PMID: 34894807.
Copy Download .nbib Format: NLM
Outpatient initiation of dofetilide: insights from the complexities of atrial fibrillation management during the COVID-19 lockdown.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing

Mascarenhas DAN, Mudumbi PC, Kantharia BK.
PMID: 33484394
J Interv Card Electrophysiol. 2021 Jan 23; doi: 10.1007/s10840-021-00942-y. Epub 2021 Jan 23.

BACKGROUND: At peak COVID-19 lockdown, patients with symptomatic atrial fibrillation (AF) were faced with an equipoise between a palliative rate-control versus cautious rhythm-control strategy, including hospitalization for initiation of antiarrhythmic drug/s (AADs) and cardiac procedures which was impossible due...

Cite
Mascarenhas DAN, Mudumbi PC, Kantharia BK. Outpatient initiation of dofetilide: insights from the complexities of atrial fibrillation management during the COVID-19 lockdown. J Interv Card Electrophysiol. 2021;doi: 10.1007/s10840-021-00942-y.
Mascarenhas, D. A. N., Mudumbi, P. C., & Kantharia, B. K. (2021). Outpatient initiation of dofetilide: insights from the complexities of atrial fibrillation management during the COVID-19 lockdown. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, . https://doi.org/10.1007/s10840-021-00942-y
Mascarenhas, Daniel A N, et al. "Outpatient initiation of dofetilide: insights from the complexities of atrial fibrillation management during the COVID-19 lockdown." Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing vol. (2021). doi: https://doi.org/10.1007/s10840-021-00942-y
Mascarenhas DAN, Mudumbi PC, Kantharia BK. Outpatient initiation of dofetilide: insights from the complexities of atrial fibrillation management during the COVID-19 lockdown. J Interv Card Electrophysiol. 2021 Jan 23; doi: 10.1007/s10840-021-00942-y. Epub 2021 Jan 23. PMID: 33484394; PMCID: PMC7823191.
Copy Download .nbib Format: NLM
HiPSC-CMs from different sex and ethnic origin donors exhibit qualitatively different responses to several classes of pharmacological challenges.

Journal of pharmacological and toxicological methods

Zeng H, Wang J, Clouse H, Lagrutta A, Sannajust F.
PMID: 31201864
J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106598. doi: 10.1016/j.vascn.2019.106598. Epub 2019 Jun 12.

We investigated whether human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) created from diverse origins could have qualitatively (not just quantitatively) different responses to pharmacological reagents. Specifically, we challenged six hiPSC-CM syncytia made from a female Caucasian, a female black...

Cite
Zeng H, Wang J, Clouse H, et al. HiPSC-CMs from different sex and ethnic origin donors exhibit qualitatively different responses to several classes of pharmacological challenges. J Pharmacol Toxicol Methods. 2019;99:106598doi: 10.1016/j.vascn.2019.106598.
Zeng, H., Wang, J., Clouse, H., Lagrutta, A., & Sannajust, F. (2019). HiPSC-CMs from different sex and ethnic origin donors exhibit qualitatively different responses to several classes of pharmacological challenges. Journal of pharmacological and toxicological methods, 99106598. https://doi.org/10.1016/j.vascn.2019.106598
Zeng, Haoyu, et al. "HiPSC-CMs from different sex and ethnic origin donors exhibit qualitatively different responses to several classes of pharmacological challenges." Journal of pharmacological and toxicological methods vol. 99 (2019): 106598. doi: https://doi.org/10.1016/j.vascn.2019.106598
Zeng H, Wang J, Clouse H, Lagrutta A, Sannajust F. HiPSC-CMs from different sex and ethnic origin donors exhibit qualitatively different responses to several classes of pharmacological challenges. J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106598. doi: 10.1016/j.vascn.2019.106598. Epub 2019 Jun 12. PMID: 31201864.
Copy Download .nbib Format: NLM
Inhibition of K.

Frontiers in pharmacology

Diness JG, Abildgaard L, Bomholtz SH, Skarsfeldt MA, Edvardsson N, Sørensen US, Grunnet M, Bentzen BH.
PMID: 32508659
Front Pharmacol. 2020 May 20;11:749. doi: 10.3389/fphar.2020.00749. eCollection 2020.

BACKGROUND: Hypokalemia reduces the cardiac repolarization reserve. This prolongs the QT-interval and increases the risk of ventricular arrhythmia; a risk that is exacerbated by administration of classical class 3 anti-arrhythmic agents.Small conductance CaPURPOSE: To study the effects of pharmacological...

Cite
Diness JG, Abildgaard L, Bomholtz SH, et al. Inhibition of K. Front Pharmacol. 2020;11:749doi: 10.3389/fphar.2020.00749.
Diness, J. G., Abildgaard, L., Bomholtz, S. H., Skarsfeldt, M. A., Edvardsson, N., Sørensen, U. S., Grunnet, M., & Bentzen, B. H. (2020). Inhibition of K. Frontiers in pharmacology, 11749. https://doi.org/10.3389/fphar.2020.00749
Diness, Jonas Goldin, et al. "Inhibition of K." Frontiers in pharmacology vol. 11 (2020): 749. doi: https://doi.org/10.3389/fphar.2020.00749
Diness JG, Abildgaard L, Bomholtz SH, Skarsfeldt MA, Edvardsson N, Sørensen US, Grunnet M, Bentzen BH. Inhibition of K. Front Pharmacol. 2020 May 20;11:749. doi: 10.3389/fphar.2020.00749. eCollection 2020. PMID: 32508659; PMCID: PMC7251152.
Copy Download .nbib Format: NLM
The Use of Intravenous Lidocaine in the Setting of Chronic Dofetilide Overdose: A Case Report.

Journal of pharmacy practice

Zhu E, Gabriele M, Nguyen MT.
PMID: 33982631
J Pharm Pract. 2021 May 13;8971900211015053. doi: 10.1177/08971900211015053. Epub 2021 May 13.

Managing the risks and consequences of long QT syndrome can be challenging. Multiple factors contribute to the prolongation of the heart-rate corrected QT (QTc) interval including many drug-drug and drug-disease state interactions. Current literature is often focused on avoiding...

Cite
Zhu E, Gabriele M, Nguyen MT. The Use of Intravenous Lidocaine in the Setting of Chronic Dofetilide Overdose: A Case Report. J Pharm Pract. 2021;8971900211015053doi: 10.1177/08971900211015053.
Zhu, E., Gabriele, M., & Nguyen, M. T. (2021). The Use of Intravenous Lidocaine in the Setting of Chronic Dofetilide Overdose: A Case Report. Journal of pharmacy practice, 8971900211015053. https://doi.org/10.1177/08971900211015053
Zhu, Eric, et al. "The Use of Intravenous Lidocaine in the Setting of Chronic Dofetilide Overdose: A Case Report." Journal of pharmacy practice vol. (2021): 8971900211015053. doi: https://doi.org/10.1177/08971900211015053
Zhu E, Gabriele M, Nguyen MT. The Use of Intravenous Lidocaine in the Setting of Chronic Dofetilide Overdose: A Case Report. J Pharm Pract. 2021 May 13;8971900211015053. doi: 10.1177/08971900211015053. Epub 2021 May 13. PMID: 33982631.
Copy Download .nbib Format: NLM
Inhibition of K.

Frontiers in pharmacology

Citerni C, Kirchhoff J, Olsen LH, Sattler SM, Grunnet M, Edvardsson N, Bentzen BH, Diness JG.
PMID: 32435191
Front Pharmacol. 2020 May 06;11:556. doi: 10.3389/fphar.2020.00556. eCollection 2020.

BACKGROUND: Inhibition of KMETHODS: Landrace pigs were randomized into an AF group (n = 6) and two control groups: SHAM1 (n = 8) and SHAM2 (n = 4). AF pigs were atrially tachypaced (A-TP) for 43 ± 4 days...

Cite
Citerni C, Kirchhoff J, Olsen LH, et al. Inhibition of K. Front Pharmacol. 2020;11:556doi: 10.3389/fphar.2020.00556.
Citerni, C., Kirchhoff, J., Olsen, L. H., Sattler, S. M., Grunnet, M., Edvardsson, N., Bentzen, B. H., & Diness, J. G. (2020). Inhibition of K. Frontiers in pharmacology, 11556. https://doi.org/10.3389/fphar.2020.00556
Citerni, Carlotta, et al. "Inhibition of K." Frontiers in pharmacology vol. 11 (2020): 556. doi: https://doi.org/10.3389/fphar.2020.00556
Citerni C, Kirchhoff J, Olsen LH, Sattler SM, Grunnet M, Edvardsson N, Bentzen BH, Diness JG. Inhibition of K. Front Pharmacol. 2020 May 06;11:556. doi: 10.3389/fphar.2020.00556. eCollection 2020. PMID: 32435191; PMCID: PMC7219273.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 61 entries